Individuals with primary and pharmacologic B cell deficiencies have high rates of severe
disease and mortality from coronavirus disease 2019 (COVID-19), but the immune …

Background Myasthenia gravis (MG) and the experimental autoimmune MG (EAMG) animal
model are characterized by T-cell-induced and B-cell-dominated autoimmune diseases that …

Regulatory B cells (Bregs) are immunosuppressive cells that support immunological
tolerance by the production of IL‐10, IL‐35, and TGF‐β. Bregs arise from different …

Background Anti-CD20 is a highly effective therapy for multiple sclerosis (MS), a disease
with multiple abnormalities in function of B and T cells and innate immune cells. Anti-CD20 …

Purpose Studies on overall immune infiltration and pyroptosis in patients with multiple
sclerosis (MS) are limited. This study explored immune cell infiltration and pyroptosis in MS …

Multiple sclerosis (MS) is an inflammatory neurodegenerative disorder with putative
autoimmune origin. The disease starts earlier than current diagnostic criteria can detect and …

IgG4 subclass antibodies represent the rarest subclass of IgG antibodies, comprising only 3-
5% of antibodies circulating in the bloodstream. These antibodies possess unique structural …

Objective Repeated intravenous administration of anti‐CD20 depleting monoclonal
antibodies 6 months apart is among the highly effective treatment options in multiple …

B cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting
(RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological …

The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary
progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however …